

Asia-Pacific Consulting and Appraisal Limited
Flat/Room A 12F ZJ 300, 300 Lockhart Road, Wanchai, Hong Kong

Attn.: The Board of Directors

22 December 2023

Dear Sir/Madam

ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED (the *Company*)
(1) DISCLOSEABLE AND CONNECTED TRANSACTION
(2) NON-EXEMPT CONTINUING CONNECTED TRANSACTIONS

We refer to the circular of the Company dated 22 December 2023 (the *Circular*) relating to the captioned matter. Unless otherwise specified, capitalised terms used herein shall bear the same meanings as those defined in the Circular.

We hereby consent to the issue of the Circular with the inclusion of the Valuation Report dated 27 November 2023 relating to the Proposed Acquisition as set out in the section headed “Valuation Report of the Target Business” of the Circular and references to our name in the form and context in which they respectively are included in the Circular, and to such Valuation Report and this letter being made available for public inspection. We also confirm that we have no reason to withdraw the above consent as at the date hereof.

We confirm that as at the Latest Practicable Date, (a) we were not and are not interested in any securities of any member of the Group, nor did we have any right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for securities in any member of the Group; and (b) we did not have any material direct or indirect interest in any material assets, which had since 31 March 2023 (being the date to which the latest published audited financial statements of the Group were made up) been acquired or disposed of by or leased to any member of the Group, or were proposed to be acquired or disposed of by or leased to any member of the Group.

Yours faithfully
For and on behalf of
Asia-Pacific Consulting and Appraisal Limited



Jack W. J. Li
CFA, MRICS, MBA
Partner